C4 Therapeutics competitors

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.

Mr. Newell has over 20 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 15 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at SutroVax Inc. Mr. Newell is also a Board member on BIO’s Emerging Companies Section and Health Section and Chairman of the Board and a member of the Executive Committee of the California Life Sciences Association.

David Rooklin is a Founder & CEO at Redesign Science; Cofounder at Redesign Science; and Research Intern, Cardiovascular Disease Department at MERCK & CO., INC. and is based in New York City, New York. He has worked as Reserach Associate at New York University and Research Technician, Josef Michl Lab at University of Colorado Boulder. David studied at New York University between 2006 and 2012 and Oberlin College between 1998 and 2002.

Rami joined Arcellx in 2021 and serves as the Chairman and Chief Executive Officer. Most recently, Rami served as President and CEO of Nevro, where he joined in 2012. Under his leadership, Nevro grew from a small private company to a public company approaching $400m in revenue and a leader in neuromodulation. Prior to Nevro, Rami was an investor with Johnson & Johnson Development Corporation (JJDC), where he led several investments including Nevro’s Series B Financing and served on the Board of Directors of several private companies including Nevro’s. Prior to joining JJDC, Rami was a Design Engineer for Advanced Neuromodulation Systems, Inc. where he led firmware design and development on several implantable spinal cord stimulators. Rami earned recognition as an EY Entrepreneur of the Year, as one of the top CEOs in the U.S. and as one of the top CEOs for women and diversity. He is a recipient of the Bill Campbell award by Watermark for his influence, impact, and advocacy in promoting women and women’s issues. Rami received a MBA from the Wharton School of the University of Pennsylvania and holds a BS in Electrical and Computer Engineering from Rutgers University School of Engineering.

John Fowler is a Managing Director at Montebello Holdings, Co-Founder and CEO at Kezar Life Sciences Inc, and Board Member at Kezar Life Sciences Inc and is based in South San Francisco, California. He has worked as Management Consultant at William Kent International, CEO at Aero Logistics, and Managing Director at Montebello Capital. John studied at Stanford Graduate School of Business between 1998 and 2000 and Stanford University between 1989 and 1993.

Dr. Worland has served as a member of the board of directors since February 2015. Dr. Worland is currently President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a company focused on new treatments for cancer, where he has served since May 2012. Previously, Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for hepatitis C and cancer, from August 2007 until the company’s acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named Chief Executive Officer, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career at Agouron Pharmaceuticals, Inc. and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University. Dr. Worland received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.